AT
Aeterna Therapeutics
The startup develops proprietary monoclonal antibodies targeting oncology and metabolic disorders, utilizing advanced antibody engineering techniques to enhance specificity and efficacy. By addressing the need for effective treatments in these complex diseases, the company aims to improve patient outcomes and reduce healthcare costs.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops proprietary monoclonal antibodies targeting oncology and metabolic disorders, utilizing advanced antibody engineering techniques to enhance specificity and efficacy. By addressing the need for effective treatments in these complex diseases, the company aims to improve patient outcomes and reduce healthcare costs.